Bend Research Expands Analytical Sciences Capabilities and Capacity for Pharmaceutical Development

Bend Research Inc., an independent drug-formulation development and manufacturing company, has expanded its Good Manufacturing Practice (GMP) analytical capabilities and capacity for pharmaceutical development.

Coupled with the company’s existing analytical-method development capabilities, Bend Research has added on-site stability storage and additional GMP testing to efficiently support manufacture of high-quality supplies for clinical use.

The new onsite stability storage will reduce the need to ship samples to a subcontractor, offering clients the enhanced effectiveness of a single vendor. Formulations can be stored at conditions ranging from 5⁰C to 40⁰C/75% RH, meeting industry-standard stability-testing conditions suggested by the International Conference on Harmonization (ICH).

“Our customers asked us to add this on-site capability and we were happy to provide the service. Having this capability on-site will reduce the risks associated with stability sample shipment. It also provides our clients with more rapid product testing and more control,” said Tanya Hayden, Bend Research Vice President.

In addition to stability and release testing, Bend Research continues to offer analytical-method development and method validation for drug products and intermediates in a world-class Quality Control laboratory. The company recently added instrumentation to its existing suite of GMP-qualified equipment. The new instruments, which include a differential scanning particle-size analyzer, will increase capacity and offer clients additional GMP testing options in a single laboratory.

According to Hayden, this expansion is part of a continuing effort by Bend Research to offer its clients quick-to-clinic, full-service analytical capabilities, from drug concept to commercialization.

About Bend Research Inc.

For more than 35 years, Bend Research has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company’s ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding.

Bend Research capabilities include formulation and dosage-form support, process development and optimization, manufacture of clinical-trial quantities of drug candidates in its GMP facilities, and advancement of promising drug candidates from conception through commercialization. Bend Research is a leader in novel formulations, including spray-dried dispersions (SDDs) and hot-melt extrudates, and modified-release, inhalation, and biotherapeutics technologies.

With more than 285 employees, Bend Research Inc. is based in six state-of-the-art facilities in Bend, Oregon, USA.

Research on LinkedIn at http://www.linkedin.com/company/bend-research. For more information, visit www.bendresearch.com.